KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 581 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data. PMID 40416880 · Front Oncol · 2025 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 3 Panel · risk visible
Comparison of immune checkpoint inhibitors in combination with chemotherapy versus chemotherapy alone in the first-line treatment of advanced gastric cancer patients with low PD-L1 expression: a systematic review and meta-analysis. PMID 40351322 · Ther Adv Med Oncol · 2025 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial. PMID 40231258 · Front Oncol · 2025 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 8 Panel · risk visible
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). PMID 40083872 · Front Oncol · 2025 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 17 Panel · risk visible
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. PMID 39293462 · Lancet · 2024-Sep-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 4 Panel · risk visible
CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma. PMID 39058951 · Blood Adv · 2024-Sep-24 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 6 Panel · risk visible
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial. PMID 39300077 · Signal Transduct Target Ther · 2024-Sep-19 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. PMID 39271684 · Blood Cancer J · 2024-Sep-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer. PMID 38990098 · Clin Cancer Res · 2024-Sep-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 4 Figure · 7 Panel · risk visible
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. PMID 39266535 · NPJ Breast Cancer · 2024-Sep-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 6 Panel · risk visible
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial. PMID 39018515 · J Clin Oncol · 2024-Sep-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 4 Panel · risk visible
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial. PMID 38502052 · Neuro Oncol · 2024-Sep-05 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 4 Panel · risk visible
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study. PMID 38913539 · Endocr Relat Cancer · 2024-Sep-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). PMID 38775718 · J Natl Cancer Inst · 2024-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 3 Panel · risk visible
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab. PMID 39399157 · JTO Clin Res Rep · 2024-Sep 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 6 Panel · risk visible
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. PMID 39162049 · J Comp Eff Res · 2024-Sep 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 5 Panel · risk visible
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). PMID 38967884 · Breast Cancer Res Treat · 2024-Sep 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial. PMID 38872480 · J Gynecol Oncol · 2024-Sep 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 2 Panel · risk visible
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. PMID 39058954 · Blood Adv · 2024-Oct-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 5 Panel · risk visible
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109). PMID 39375745 · Breast Cancer Res · 2024-Oct-07 The record describes a primary analysis of a Phase III randomized trial with a drug intervention and time-to-event efficacy endpoints. Randomization is explicitly stated in the study design ('PALLAS is an open, international, phase 3 study...'). The analysis is of the original intention-to-treat population, not a post-hoc subgroup, and includes key efficacy endpoints.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 2 Figure · 3 Panel · risk visible
Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. PMID 39418020 · JAMA Netw Open · 2024-Oct-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 8 Panel · risk visible
Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. PMID 39461775 · ESMO Open · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 5 Figure · 10 Panel · risk visible
Tislelizumab plus chemotherapy as first-line treatment of locally advanced or metastatic nonsquamous non-small-cell lung cancer (final analysis of RATIONALE-304: a randomized phase III trial). PMID 39461773 · ESMO Open · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. PMID 39435271 · Liver Cancer · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study. PMID 39435268 · Liver Cancer · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 6 Figure · 6 Panel · risk visible
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial. PMID 39364270 · EClinicalMedicine · 2024-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 3 Panel · risk visible
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. PMID 39221992 · Cancer Commun (Lond) · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 1 Panel · risk visible
Characteristics and outcome of synchronous bilateral Wilms tumour in the SIOP WT 2001 Study: Report from the SIOP Renal Tumour Study Group (SIOP-RTSG). PMID 39080350 · Br J Cancer · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 4 Figure · 6 Panel · risk visible
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. PMID 38992123 · Nat Med · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 2 Panel · risk visible
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. PMID 38888616 · Ann Hematol · 2024-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. PMID 39547252 · Lancet · 2024-Nov-23 The record describes a randomized, open-label clinical trial in human oncology patients. It is a phase II/III trial (SU2C-SARC032) with a drug intervention (pembrolizumab) and reports formal primary efficacy results for disease-free survival (a time-to-event endpoint) with hazard ratio and Kaplan-Meier analysis. The trial is not post-hoc, subgroup, or safety-only. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 8 Figure · 11 Panel · risk visible
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. PMID 39437804 · Lancet Oncol · 2024-Nov 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. PMID 38683596 · JAMA · 2024-May-28 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. PMID 38452313 · J Clin Oncol · 2024-May-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 6 Panel · risk visible
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data. PMID 38713408 · Cancer Immunol Immunother · 2024-May-07 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 3 Panel · risk visible
Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. PMID 38350047 · J Clin Oncol · 2024-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 5 Panel · risk visible
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. PMID 38796287 · ESMO Open · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 1 Figure · 2 Panel · risk visible
Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes. PMID 38785215 · Cancer Med · 2024-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 8 Panel · risk visible
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma. PMID 38744099 · ESMO Open · 2024-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H L S B
旧组与严格 v3 交集 eligibleexplicit_phase3_randomized confirmed 2 Figure · 5 Panel · risk visible
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PMID 38728364 · PLoS Med · 2024-May Meets all eligibility criteria: oncology, human, randomized, phase III/definitive, time-to-event endpoint (PFS), drug intervention, and original result report.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. PMID 38716626 · Cancer Med · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 12 Panel · risk visible
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. PMID 38692082 · ESMO Open · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 3 Figure · 4 Panel · risk visible
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. PMID 38642472 · ESMO Open · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 2 Figure · 10 Panel · risk visible
Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial. PMID 38618203 · EClinicalMedicine · 2024-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 1 Panel · risk visible
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. PMID 38588696 · Nature · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type confirmed 5 Figure · 17 Panel · risk visible
Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial. PMID 38538861 · Leukemia · 2024-May 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type confirmed 1 Figure · 6 Panel · risk visible
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. PMID 38308771 · Gastric Cancer · 2024-May 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer. PMID 38181323 · J Clin Oncol · 2024-Mar-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 1 Figure · 2 Panel · risk visible
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. PMID 38485190 · J Immunother Cancer · 2024-Mar-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 7 Panel · risk visible
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer. PMID 38439079 · Breast Cancer Res · 2024-Mar-04 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 6 Panel · risk visible